Mayne Pharma Group (AU:MYX)

Mayne Pharma Group (MYX) Financial Statements


Mayne Pharma Group Financial Overview

Mayne Pharma Group's market cap is currently ―. The company's EPS TTM is AU$-3.698; its P/E ratio is -1.44; Mayne Pharma Group is scheduled to report earnings on February 26, 2024, and the estimated EPS forecast is AU$-0.46. See an overview of income statement, balance sheet, and cash flow financials.
Jun 22Jun 21Jun 20Jun 19Jun 18
Income Statement-
Total Revenue-----
Gross Profit-----
Net Income Common Stockholders-----
Balance Sheet-
Cash, Cash Equivalents and Short-Term InvestmentsAU$ 96.67MAU$ 97.98MAU$ 137.78MAU$ 89.00MAU$ 94.06M
Total AssetsAU$ 1.29BAU$ 1.46BAU$ 1.83BAU$ 1.64BAU$ 1.83B
Total DebtAU$ 413.67MAU$ 346.82MAU$ 398.05MAU$ 369.38MAU$ 374.19M
Net DebtAU$ 316.99MAU$ 248.84MAU$ 260.26MAU$ 280.38MAU$ 280.13M
Total LiabilitiesAU$ 730.81MAU$ 691.61MAU$ 782.87MAU$ 622.26MAU$ 595.35M
Stockholders EquityAU$ 564.77MAU$ 768.36MAU$ 1.04BAU$ 1.01BAU$ 1.23B
Cash Flow-
Free Cash Flow-----
Operating Cash Flow-----
Investing Cash Flow-----
Financing Cash Flow-----
Currency in AUD

Mayne Pharma Group Earnings and Revenue History

Mayne Pharma Group Debt to Assets

Mayne Pharma Group Cash Flow

Mayne Pharma Group Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis